<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01773954</url>
  </required_header>
  <id_info>
    <org_study_id>ATLAS</org_study_id>
    <secondary_id>20122054</secondary_id>
    <nct_id>NCT01773954</nct_id>
  </id_info>
  <brief_title>Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration</brief_title>
  <acronym>ATLAS</acronym>
  <official_title>Optical Coherence Tomography Guided Treat and Extend Therapy for Neovascular Age Related Macular Degeneration Using Aflibercept (the ATLAS Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MidAtlantic Retina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the visual outcome and number of injections required during an optical coherence&#xD;
      tomography (OCT)-guided treat and extend regimen with intravitreal aflibercept for treatment&#xD;
      of subfoveal neovascular age-related macular degeneration (NVAMD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to see how using &quot;treat and extend,&quot; a method of determining how&#xD;
      often a patient with NVAMD should visit the retina clinic and receive treatments, affects&#xD;
      vision in patients with this condition after treatment. The treatment the investigators are&#xD;
      using in this study is an eye injection of a drug called aflibercept (also called EYLEA).&#xD;
      Eylea is FDA (Food and Drug Administration) approved for treatment of wet age related macular&#xD;
      degeneration.&#xD;
&#xD;
      The investigators hope that &quot;treat and extend&quot; strikes the right balance between making sure&#xD;
      patients get all of the treatments needed, but not giving patients too many treatments (so&#xD;
      that the side effects of treatments are minimized and so that patients don't have to make&#xD;
      more visits than they need to maintain maximum visual gain). The experimental part of this&#xD;
      study is determining this &quot;right balance&quot; of eye injections.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2013</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Change in Total Thickness at the Foveal Center Point on OCT</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Intravitreal Aflibercept Injection More</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receives treatment at baseline and week 4 visit. The first time extension criteria are met the follow-up interval will be increased by 4 weeks. Each time the extension criteria is met the interval will be extended by 2 weeks to a maximum of 16 weeks. If a patient is being followed at an 8 week interval but fails to meet extension criteria at a particular visit, treatment will be administered as usual and the follow up interval will be reduced to 4 weeks. If patient is being followed at 10-16 week interval but fails to meet extension criteria at a particular visit, treatment will be administered but the follow-up interval will be reduced by 2 week increments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal Aflibercept Injection</intervention_name>
    <description>Increased or decreased time between visits</description>
    <arm_group_label>Intravitreal Aflibercept Injection More</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients older than 55 years with treatment naïve, active subfoveal NVAMD&#xD;
             demonstrating macular fluid on optical coherence tomography (OCT) and leakage on&#xD;
             fluorescein angiography (FA).&#xD;
&#xD;
          -  Only one eye for each patient demonstrating a pre-treatment acuity of 20/25 - 20/320&#xD;
             is eligible&#xD;
&#xD;
          -  Patients cannot have concurrent progressive retinal disease in the study eye.&#xD;
&#xD;
          -  Willing and able to comply with clinic visits and study-related procedures&#xD;
&#xD;
          -  Provide signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment for NVAMD in the study eye,&#xD;
&#xD;
          -  Prior experimental treatment of NVAMD in either eye&#xD;
&#xD;
          -  Prior treatment with systemic anti-VEGF (vascular endothelial growth factor) agents&#xD;
&#xD;
          -  Prior treatment with verteporfin, plaque brachytherapy, or external-beam radiation&#xD;
             therapy, or transpupillary thermotherapy in the study eye&#xD;
&#xD;
          -  Previous subfoveal focal laser photocoagulation involving the foveal center in the&#xD;
             study eye&#xD;
&#xD;
          -  History of vitreo surgical intervention in the study eye. Cataract surgery is&#xD;
             permitted.&#xD;
&#xD;
          -  Concurrent eye disease in the study eye that could compromise visual acuity (e.g.&#xD;
             diabetic retinopathy, advanced glaucoma)&#xD;
&#xD;
          -  Any concurrent intraocular condition in the study eye (e.g. diabetic retinopathy or&#xD;
             glaucoma) that, in the opinion of the investigator, could either&#xD;
&#xD;
          -  require medical or surgical intervention during the 52 weeks study period to prevent&#xD;
             or treat visual loss that might result from that condition, or&#xD;
&#xD;
          -  allowed to progress untreated, could likely contribute to loss of at least 2 Snellen&#xD;
             equivalent lines of best corrected visual acuity over the 52 weeks study period&#xD;
&#xD;
          -  Active intraocular inflammation (grade trace or above) in the study eye, or history of&#xD;
             idiopathic or autoimmune-associated uveitis in either eye&#xD;
&#xD;
          -  Current vitreous hemorrhage in the study eye&#xD;
&#xD;
          -  History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the&#xD;
             study eye&#xD;
&#xD;
          -  Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either&#xD;
             eye&#xD;
&#xD;
          -  Aphakia, Anterior Chamber Intraocular Lens (ACIOL), or unstable Posterior Chamber&#xD;
             Intraocular Lens (PCIOL).&#xD;
&#xD;
          -  Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg&#xD;
             despite treatment with anti-glaucoma medication)&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Sexually active men* or women of childbearing potential** who are unwilling to&#xD;
             practice adequate contraception during the study (adequate contraceptive measures&#xD;
             include stable use of oral contraceptives or other prescription pharmaceutical&#xD;
             contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device&#xD;
             [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or&#xD;
             jelly, or diaphragm plus contraceptive sponge, foam, or jelly)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl Regillo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wills Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mid Atlantic Retina- Cherry Hill</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina- Huntingdon Valley</name>
      <address>
        <city>Huntingdon Valley</city>
        <state>Pennsylvania</state>
        <zip>19006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina- Wills Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>January 17, 2013</study_first_submitted>
  <study_first_submitted_qc>January 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2013</study_first_posted>
  <results_first_submitted>October 6, 2017</results_first_submitted>
  <results_first_submitted_qc>April 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 2, 2018</results_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>MidAtlantic Retina</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>amd</keyword>
  <keyword>age related macular degeneration</keyword>
  <keyword>macular degeneration</keyword>
  <keyword>neovascular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intravitreal Aflibercept</title>
          <description>Intravitreal aflibercept on treat and extend schedule</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intravitreal Aflibercept</title>
          <description>Intravitreal aflibercept on treat and extend schedule</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.3" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score</title>
        <time_frame>Baseline to Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravitreal Aflibercept</title>
            <description>Intravitreal aflibercept on treat and extend schedule</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score</title>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="2.9" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Total Thickness at the Foveal Center Point on OCT</title>
        <time_frame>Baseline to Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravitreal Aflibercept</title>
            <description>Intravitreal aflibercept on treat and extend schedule</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Thickness at the Foveal Center Point on OCT</title>
          <units>micrometers</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-143" lower_limit="-187" upper_limit="-99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intravitreal Aflibercept</title>
          <description>Intravitreal aflibercept on treat and extend schedule</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Fatal MI</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is a non-controlled, non-comparative open label study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michele Formoso</name_or_title>
      <organization>Mid Atlantic Retina</organization>
      <phone>215-928-3092</phone>
      <email>research@midatlanticretina.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

